High-dose hydroxyurea with differentiating agents for treating ultra-high-risk acute promyelocytic leukemia in resource-challenged settings.
Singh C, Wadhera S, Yanamandra U, Karunakaran P, Jindal N, Kumar SR, Saini N, Jandial A, Jain A, Das C, Prakash G, Khadwal A, Naseem S, Das R, Varma N, Varma S, Malhotra P, Lad D.
Singh C, et al. Among authors: khadwal a.
Acta Oncol. 2022 Dec;61(12):1512-1514. doi: 10.1080/0284186X.2022.2162347. Epub 2022 Dec 29.
Acta Oncol. 2022.
PMID: 36579788
No abstract available.